Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 6/20 | 0.73 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069708 | 0.91 | HSPB1 (0.68) | HSPB1PDE7AMAPTMEN1KMT2A | |
| SCHEMBL27859313 | 0.87 | HSPB1 (0.82) | HSPB1PDE7AMAPTMEN1KMT2A | |
| SCHEMBL4373270 | 0.84 | HSPB1 (1.00) | HSPB1PDE7AMAPTMEN1KMT2A | |
| Nitrofen SCHEMBL1702412 | 0.84 | PDE7A (0.68) | HSPB1PDE7AMAPTMEN1KMT2A | |
| Nitrofen SCHEMBL38981 | 0.84 | PDE7A (0.68) | HSPB1PDE7AMAPTMEN1KMT2A | |
| Nitrofen SCHEMBL29364713 | 0.84 | PDE7A (0.68) | HSPB1PDE7AMAPTMEN1KMT2A | |
| SCHEMBL28317228 | 0.84 | ALDH1A1 (0.53) | HSPB1PDE7AMAPTMEN1KMT2A | |
| SCHEMBL11475236 | 0.83 | PDE7A (0.76) | HSPB1PDE7AMAPTMEN1KMT2A | |
| Nitrofen SCHEMBL28057303 | 0.83 | PDE7A (0.67) | HSPB1PDE7AMAPTMEN1KMT2A | |
| SCHEMBL10564929 | 0.82 | HSPB1 (0.73) | HSPB1PDE7AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539253-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539253-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539253-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-9133131-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133131-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133131-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013072758-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072758-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, P2RX3, CACNA1A | HSPB1 2170/4885PDE7A 744/4885MAPT 3998/4885 |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, P2RX3, CACNA1A | HSPB1 2170/4885PDE7A 744/4885MAPT 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.